Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Chairman’s Address to Shareholders 2019 Annual General Meeting

November 26, 2019November 26, 2019 Alterity Therapeutics

Chairman’s Address to Shareholders 2019 AGM

Post navigation

AGM 2019 Presentation

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Related Posts

Alterity Therapeutics’ Finance News Network Presentation

July 9, 2019July 9, 2019

Alterity Therapeutics talks to Finance News Network

July 9, 2019July 9, 2019

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

July 29, 2019July 29, 2019

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent Posts

New data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065